Wire · opportunities
High Q Technologies Expands Quantum Protein Analysis Platform For Alzheimer's Drug Discovery
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
High Q Technologies has expanded its quantum-enabled electron paramagnetic resonance (EPR) platform, Fathom, for accelerated drug discovery in Alzheimer's and neurodegenerative diseases by capturing multiple protein configurations simultaneously. The company has partnered with contract research organization Creative Biostructure to broaden global access to the technology.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're selling structural biology tools or running a CRO, you've just lost your monopoly on protein dynamics data. High Q's partnership with Creative Biostructure puts quantum EPR into 3,000 pharma labs within months—your customers now have a faster path to early-stage insights, which means they'll demand the same speed from you or leave.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics